Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon?

/by

Authors: Renata Androvicova, Jiri Horacek, Tibor Stark, Filippo Drago, Vincenzo Micale
Pharmacological Research, January 2017
—
The endocannabinoid system (ECS), which is composed of the cannabinoid receptors types 1 and 2 (CB1 and CB2) for marijuana’s psychoactive ingredient Δ9-tetrahydrocannabinol (Δ9-THC), the endogenous ligands (AEA and 2-AG) and the enzymatic systems involved in their biosynthesis…

Read more

Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies.

/by

Authors: Javier Fernández-Ruiz, María Gómez-Ruiz, Concepción García, Mariluz Hernández, José A. Ramos
Methods in Enzymology, 2017
—
The increase in lifespan during the last 50 years, mainly in developed countries, has originated a progressive elevation in the incidence of chronic neurodegenerative disorders, for which aging is the key risk factor. This fact will definitively become the major biomedical cha…

Read more

Cannabinoid Type-2 Receptor Drives Neurogenesis and Improves Functional Outcome After Stroke.

/by

Authors: Isabel Bravo-Ferrer, María I. Cuartero , Juan G. Zarruk, Jesús M. Pradillo, Olivia Hurtado, et al
Stroke, January 2017
—
BACKGROUND AND PURPOSE: Stroke is a leading cause of adult disability characterized by physical, cognitive, and emotional disturbances. Unfortunately, pharmacological options are scarce. The cannabinoid type-2 receptor (CB2R) is neuroprotective in acute experimental stroke by …

Read more